Stellantis US Sales Momentum Builds, but European Drag and FCF Test Remain

What happened

Stellantis reported first-half 2026 US sales up 5% YoY, with June up 10% and Q2 up 6%, citing momentum from its FaSTLAne 2030 plan and America250 tie-ins. The headline progress, however, masks a still-weak European industrial picture, with Italian output at 68-year lows and structural EV price cuts compressing margins. The DeepValue report cautions that while US reinvestment may eventually lift volumes, the path to positive industrial free cash flow remains uncertain given simultaneous capex and negative working capital dynamics. Governance flux and a lack of permanent CEO add execution risk, and the stock's low multiples reflect deep skepticism of a clean turnaround. This US sales data is a welcome uptick but does not yet provide the evidence of margin and cash flow recovery needed to justify upgrading from a WAIT stance.

Implication

The stock's 2.9x P/E and 0.7x P/B already discount significant risk, so any positive US data can catalyze a short-term rally. However, without corresponding improvement in European utilization and industrial free cash flow, the recovery narrative lacks full credibility. Investors should monitor the 2026 Capital Markets Day for updated margin targets and CEO clarity before committing. The US news improves the probability of the base case ($13) slightly, but the 30% bear case risk remains elevated. Until European headwinds abate and FCF turns positive, patience is warranted.

Thesis delta

The US sales data marginally increases confidence in the North America recovery trajectory, but it does not alter the core thesis that Stellantis needs both US margin improvement and European utilization recovery to unlock value. The primary shift is from 'waiting for any positive signal' to 'waiting for confirmation that US momentum is sustainable and profitable.' The WAIT rating remains appropriate, though the trim-above level ($14.50) becomes slightly more plausible if US trends continue.